In 2018, Grigor et al. developed a multiplex panel, consisting of Programmed Death-1 (PD-1), Programmed Death Ligand 1 (PD-L1), OX40, CD27, T-cell immunoglobulin, and mucin domain-containing-3 (TIM-3), along with the T cell marker CD3, allowing the detection of several immune checkpoint molecules in different cancers including invasive breast ductal carcinoma [11]. Here, CD274 is linked to cancer.